1-2 of 2
Gui Zhen Chen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

MRD-driven Initial Therapy of Acalabrutinib and Lenalidomide plus Rituximab (ALR) or Obinutuzumab (ALO) for Mantle Cell Lymphoma

Open Access
Clinical Trials & Observations
Jia Ruan, David A Bond, Bijal D Shah, John N. Allan, Sarah C. Rutherford, Caitlin Gribbin, Zhengming Chen, Bhavneet Bhinder, Wayne Tam, Davide Rossi, Jenny Z Xiang, Brittany Hobbie, Melinda Harbhajan, Tejasvi K Sahni, Gui Zhen Chen, Michael Sigouros, Giorgio GA Inghirami, Selina Chen-Kiang, Olivier Elemento, Kami J Maddocks, John P. Leonard, Peter Martin
Journal: Blood Advances
Blood Adv bloodadvances.2025017760.
https://doi.org/10.1182/bloodadvances.2025017760
Published: 2025
Includes: Supplemental data
Journal Articles

Nine-year follow-up of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma

Free
Clinical Trials & Observations
Samuel Yamshon, Gui Zhen Chen, Caitlin Gribbin, Paul Christos, Bijal Shah, Stephen J. Schuster, Sonali M. Smith, Jakub Svoboda, Richard R. Furman, John P. Leonard, Peter Martin, Jia Ruan
Journal: Blood Advances
Blood Adv (2023) 7 (21): 6579–6588.
https://doi.org/10.1182/bloodadvances.2023010606
Published: 2023